Researchers at the University of Birmingham have identified a specific biological target that could help reduce harmful inflammation in the brain. The study, published in the journal Brain, focuses on the P2X7 receptor, a protein structure that triggers inflammatory signaling when activated. By blocking this receptor, the team was able to significantly lower inflammation levels in human brain tissue.
This discovery offers a potential new avenue for treating a wide range of neurological and psychiatric conditions. Neuroinflammation is believed to play a significant role in the progression of diseases such as Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury (TBI). It is also linked to psychiatric conditions including depression and psychosis.
Targeting the P2X7 Receptor
The research team, led by Professor Nicholas Barnes, investigated how the P2X7 receptor influences the brain’s immune response. The receptor is known to promote the release of cytokines, which are proteins that regulate inflammatory responses. When the researchers applied a specific antagonist to block the P2X7 receptor, the inflammatory response in the tested human brain tissue dropped significantly.
Professor Barnes noted that this finding marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source. The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders. These include Alzheimer’s Disease, Parkinson’s, and Multiple Sclerosis, as well as inflammation-linked psychiatric conditions like schizophrenia and depression.
Developing a Scalable Model for Human Microglia
A major component of the study involved microglia, the immune cells that coordinate the brain’s response to injury and inflammation. Studying these cells has historically been difficult because they lose their defining characteristics once removed from their native brain environment. To overcome this, the researchers developed a method for converting human peripheral monocytes, a type of white blood cell collected from blood samples, into microglia-like cells.
This process mirrors a cellular transformation that occurs naturally in the brain during human aging. The resulting monocyte-derived microglia provided a powerful, scalable, and virtually unlimited platform for studying human microglial biology with unprecedented precision. When the researchers applied the P2X7 receptor antagonist to these cells, they were able to interfere with signals released by microglia as the cells became damaged and died.
After identifying the response in the lab-grown cells, the team tested whether the same findings could be reproduced in human brain tissue obtained through neurosurgical procedures. The successful results in actual human tissue strengthen the case for further investigation. The next stage for this research is the development of clinical trials in patients with neurodegenerative conditions and patients with TBI, where there are currently no effective pharmacological treatments to reduce the neuroinflammation and arising damage.
Source: ScienceDaily
